Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Ian Tapply & David C Broadway. (2021) Improving Adherence to Topical Medication in Patients with Glaucoma. Patient Preference and Adherence 15, pages 1477-1489.
Read now
Read now
Maria Fernanda Delgado, Ahmed Mostafa Abdelrahman, Malika Terahi, Juan Jose Miro Quesada Woll, Felix Gil-Carrasco, Colin Cook, Mohamed Benharbit, Sebastien Boisseau, Ernestine Chung, Yacine Hadjiat & José AP Gomes. (2019) Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement. ClinicoEconomics and Outcomes Research 11, pages 591-604.
Read now
Read now
Nevbahar Tamçelik, Belgin Izgi, Ahmet Temel, Nilgun Yildirim, Mehmet Okka, Altan Özcan, Nurşen Yüksel, Ufuk Elgin, Çiğdem Altan & Baris Ozer. (2017) Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmology 11, pages 723-731.
Read now
Read now
Gábor Holló & Andreas Katsanos. (2015) Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. Expert Opinion on Drug Safety 14:4, pages 609-617.
Read now
Read now
Katrin Lorenz & Norbert Pfeiffer. (2014) Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opinion on Pharmacotherapy 15:15, pages 2255-2262.
Read now
Read now
Kenji Inoue, Ayumi Tanaka & Goji Tomita. (2013) Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clinical Ophthalmology 7, pages 1411-1416.
Read now
Read now
Ines Lanzl, Thomas Hamacher, Klaus Rosbach, Mohammed Osman Ramez, Robert Rothe, Eva Růžičková, Marta Karhanová & Friedemann Kimmich. (2013) Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clinical Ophthalmology 7, pages 901-910.
Read now
Read now
Yang Liu & Weiming Mao. (2013) Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma. Clinical Ophthalmology 7, pages 7-14.
Read now
Read now
Kevin Kaplowitz & James C Tsai. (2012) Tafluprost in the treatment of glaucoma. Expert Review of Ophthalmology 7:5, pages 401-407.
Read now
Read now
Gemma Caterina Maria Rossi, Gian Maria Pasinetti, Marta Raimondi, Gabriella Ricciardelli, Luigia Scudeller, Mirella Blini, Alberto Amisano & Paolo Emilio Bianchi. (2012) Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients. Expert Opinion on Drug Safety 11:4, pages 519-525.
Read now
Read now
Anton Hommer & Friedemann Kimmich. (2011) Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clinical Ophthalmology 5, pages 623-631.
Read now
Read now
Marina Papadia, Alessandro Bagnis, Riccardo Scotto & Carlo E Traverso. (2011) Tafluprost for glaucoma. Expert Opinion on Pharmacotherapy 12:15, pages 2393-2401.
Read now
Read now
F. Aptel & P. Denis. (2011) Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin–timolol fixed combinations in primary open-angle glaucoma. Current Medical Research and Opinion 27:10, pages 1949-1958.
Read now
Read now
Dorota Pozarowska. (2010) Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clinical Ophthalmology 4, pages 1229-1236.
Read now
Read now
Gregory Katz, Clark L Springs, E Randy Craven & Michela Montecchi-Palmer. (2010) Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clinical Ophthalmology 4, pages 1253-1261.
Read now
Read now
Articles from other publishers (20)
Xiaoyu Zhou, Xinyue Zhang, Dengming Zhou, Yang zhao & Xuanchu Duan. (2022) A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications. Ophthalmology and Therapy 11:5, pages 1681-1704.
Crossref
Crossref
Xinghuai Sun, Qinghuai Liu, Xin Tang, Ke Yao, Yan Li, Jin Yang, Mingchang Zhang, Huiping Yuan, Yan Zheng, Weining Li & Huacong Peng. (2022) Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China. BMC Ophthalmology 22:1.
Crossref
Crossref
Farnoosh Arfaee & Arghavan Armin. (2021) A comparison between the effect of topical tafluprost and latanoprost on intraocular pressure in healthy male guinea pigs. Journal of Exotic Pet Medicine 39, pages 91-95.
Crossref
Crossref
З.Ф. Веселовская, Н.Н. Веселовская & И.Б. Запорожченко. (2021) The Effectiveness of Long-Term Use of 0.0015% Tafluprost without Preservative in Patients with Primary Open-Angle Glaucoma on the Background of Type 2 Diabetes Mellitus. Офтальмология. Восточная Европа:4, pages 579-586.
Crossref
Crossref
Toby S Al-Mugheiry & David C Broadway. (2020) Once-daily Preservative-free Topical Anti-glaucomatous Monotherapy – A Better Approach?. European Ophthalmic Review 14:1, pages 21.
Crossref
Crossref
N. I. Kurysheva, E. V. Polunina, D. D. Arzhukhanov & A. M. Tkhamadokova. (2019) Impact of tafluprost and tafluprost/timolol on the thickness of the retina in the macular area. Russian Ophthalmological Journal 12:1, pages 18-24.
Crossref
Crossref
Janika Nättinen, Antti Jylhä, Ulla Aapola, Minna Parkkari, Alexandra Mikhailova, Roger W. Beuerman & Hannu Uusitalo. (2018) Patient stratification in clinical glaucoma trials using the individual tear proteome. Scientific Reports 8:1.
Crossref
Crossref
N. I. Kurysheva, D. D. Arzhukhanov & A. M. Tkhamadokova. (2018) Effect of Tafluprost and Tafloprost/Timolol on the Optic Nerve Head, Peripapillary and Macular Microcirculation According to OCT-Angiography. Ophthalmology in Russia 15:2, pages 207-213.
Crossref
Crossref
Gábor Holló, Andreas Katsanos, Kostas G. Boboridis, Murat Irkec & Anastasios G. P. Konstas. (2017) Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. Drugs 78:1, pages 39-64.
Crossref
Crossref
Jiyoon Kwak, Seonmi Kang, Eui Ri Lee, Sangwan Park, Sungwon Park, Eunjin Park, Jaegook Lim & Kangmoon Seo. (2017) Effect of preservative-free tafluprost on intraocular pressure, pupil diameter, and anterior segment structures in normal canine eyes. Veterinary Ophthalmology 20:1, pages 34-39.
Crossref
Crossref
Soon Young Cho, Yong Yeon Kim, Chungkwon Yoo & Tae-Eun Lee. (2015) Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring. Japanese Journal of Ophthalmology 60:1, pages 27-34.
Crossref
Crossref
Du Ri Seo & Seung Joo Ha. (2015) Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops. BioMed Research International 2015, pages 1-6.
Crossref
Crossref
Murat Irkec, Banu Bozkurt & Mehmet Cem Mocan. (2013) Are preservatives necessary to improve efficacy of some glaucoma drops?. British Journal of Ophthalmology 97:12, pages 1493-1494.
Crossref
Crossref
Anastasios G P Konstas, Luciano Quaranta, Andreas Katsanos, Ivano Riva, James C Tsai, Theodoros Giannopoulos, Irini C Voudouragkaki, Eleni Paschalinou, Irene Floriani & Anna-Bettina Haidich. (2013) Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. British Journal of Ophthalmology 97:12, pages 1510-1515.
Crossref
Crossref
Parul IchhpujaniAlastair LockwoodS Jacob HengPeng Tee Khaw. 2013. Glaucoma: Basic and Clinical Perspectives. Glaucoma: Basic and Clinical Perspectives
120
134
.
Cory Swymer & Michael W Neville. (2012) Tafluprost: The First Preservative-Free Prostaglandin to Treat Open-Angle Glaucoma and Ocular Hypertension. Annals of Pharmacotherapy 46:11, pages 1506-1510.
Crossref
Crossref
Stefano Ranno, Matteo Sacchi, Cinzia Brancato, Daniela Gilardi, Andrea Lembo & Paolo Nucci. (2012) A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients. The Scientific World Journal 2012, pages 1-6.
Crossref
Crossref
Mina B. Pantcheva, Leonard K. Seibold, Nida S. Awadallah & Malik Y. Kahook. (2011) Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Advances in Therapy 28:9, pages 707-715.
Crossref
Crossref
Carl Erb, Ines Lanzl, Seid-Fatima Seidova & Friedemann Kimmich. (2011) Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Advances in Therapy 28:7, pages 575-585.
Crossref
Crossref
Clyde Schultz. (2011) Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension. Ophthalmology and Eye Diseases 3, pages OED.S4253.
Crossref
Crossref